Recombinant CA19-9 Antibody [CA19.9/1390R]
Product Specifications
Background
CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens.
Swiss Prot
NotKnown
Host
Rabbit
Reactivity
Human
Immunogen
Purified human protein used as the immunogen for the recombinant CA19-9 antibody.
Clonality
Recombinant Monoclonal
Clone
CA19.9/1390R
Conjugation
Unconjugated
Type
Primary Antibodies
Field of Research
Cancer
Purification
Protein A affinity
Concentration
0.2 mg/mL
Buffer
PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Modification
None
Shipping Conditions
Blue Ice
Storage Conditions
Aliquot and Store at 2-8˚ C. Avoid freez-thaw cycles.
Fragment
IgG, k
Applications Notes
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
Tested Applications
WB, Flow, IF, IHC-P
Physical Properties
Liquid
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
